

Miriam K Elfström

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2640948/publications.pdf>

Version: 2024-02-01

61
papers

3,299
citations

361296

20
h-index

155592

55
g-index

62
all docs

62
docs citations

62
times ranked

3385
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. <i>Lancet, The</i> , 2014, 383, 524-532.	6.3	1,282
2	HPV Vaccination and the Risk of Invasive Cervical Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 1340-1348.	13.9	723
3	Status of implementation and organization of cancer screening in The European Union Member States—Summary results from the second European screening report. <i>International Journal of Cancer</i> , 2018, 142, 44-56.	2.3	169
4	Cervical cancer screening in Europe: Quality assurance and organisation of programmes. <i>European Journal of Cancer</i> , 2015, 51, 950-968.	1.3	127
5	Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. <i>BMJ, The</i> , 2014, 348, g130-g130.	3.0	103
6	High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study. <i>PLoS Medicine</i> , 2018, 15, e1002666.	3.9	55
7	Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer. <i>British Journal of Cancer</i> , 2018, 118, 1377-1381.	2.9	43
8	Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study. <i>BMJ, The</i> , 2016, 352, i276.	3.0	40
9	Impact of HPV vaccination on cervical screening performance: a population-based cohort study. <i>British Journal of Cancer</i> , 2020, 123, 155-160.	2.9	40
10	Early assessment of the first wave of the COVID-19 pandemic on cancer screening services: The International Cancer Screening Network COVID-19 survey. <i>Preventive Medicine</i> , 2021, 151, 106642.	1.6	39
11	Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 264.e1-264.e7.	0.7	37
12	Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden. <i>PLoS Medicine</i> , 2017, 14, e1002414.	3.9	37
13	Advances in cervical cancer prevention: Efficacy, effectiveness, elimination?. <i>PLoS Medicine</i> , 2020, 17, e1003035.	3.9	36
14	Increasing participation in cervical screening by targeting long-term nonattenders: Randomized health services study. <i>International Journal of Cancer</i> , 2019, 145, 3033-3039.	2.3	32
15	Cervical cancer case-control audit: Results from routine evaluation of a nationwide cervical screening program. <i>International Journal of Cancer</i> , 2020, 146, 1230-1240.	2.3	32
16	Age at first intercourse, number of partners and sexually transmitted infection prevalence among Danish, Norwegian and Swedish women: estimates and trends from nationally representative cross-sectional surveys of more than 100 000 women. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 175-185.	1.3	31
17	Organization and quality of HPV vaccination programs in Europe. <i>Vaccine</i> , 2015, 33, 1673-1681.	1.7	28
18	Barriers to and Facilitators of Compliance with Clinic-Based Cervical Cancer Screening: Population-Based Cohort Study of Women Aged 23-60 Years. <i>PLoS ONE</i> , 2015, 10, e0128270.	1.1	25

#	ARTICLE	IF	CITATIONS
19	Registry-based assessment of the status of cervical screening in Sweden. <i>Journal of Medical Screening</i> , 2016, 23, 217-226.	1.1	24
20	Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56–60. <i>BMJ Open</i> , 2017, 7, e014788.	0.8	23
21	HPV mRNA and HPV DNA detection in samples taken up to seven years before severe dysplasia of cervix uteri. <i>International Journal of Cancer</i> , 2019, 144, 1073-1081.	2.3	22
22	Type-Specific Human Papillomavirus Biological Features: Validated Model-Based Estimates. <i>PLoS ONE</i> , 2013, 8, e81171.	1.1	21
23	Human Papillomavirus Infection Determines Prognosis in Cervical Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1522-1528.	0.8	20
24	Follow-up of women with cervical cytological abnormalities showing atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion: A nationwide cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 48.e1-48.e15.	0.7	19
25	Colposcopic and histopathologic evaluation of women with HPV persistence exiting an organized screening program. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 253.e1-253.e8.	0.7	19
26	Cervical screening and risk of adenosquamous and rare histological types of invasive cervical carcinoma: population based nested case-control study. <i>BMJ: British Medical Journal</i> , 2019, 365, l1207.	2.4	18
27	Cervical cancer screening in Sweden 2014-2016. <i>PLoS ONE</i> , 2018, 13, e0209003.	1.1	17
28	Differences in risk for SARS-CoV-2 infection among healthcare workers. <i>Preventive Medicine Reports</i> , 2021, 24, 101518.	0.8	17
29	Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination. <i>Current Opinion in Oncology</i> , 2014, 26, 120-129.	1.1	13
30	Long-term HPV type-specific risks for ASCUS and LSIL: A 14-year follow-up of a randomized primary HPV screening trial. <i>International Journal of Cancer</i> , 2015, 136, 350-359.	2.3	13
31	Initial participation as a predictor for continuous participation in population-based colorectal cancer screening. <i>Journal of Medical Screening</i> , 2018, 25, 126-133.	1.1	13
32	The cost-effectiveness of prostate cancer screening using the Stockholm3 test. <i>PLoS ONE</i> , 2021, 16, e0246674.	1.1	11
33	Interruption of cancer screening services due to COVID-19 pandemic: lessons from previous disasters. <i>Preventive Medicine Reports</i> , 2021, 23, 101399.	0.8	11
34	Surveillance systems for monitoring cervical cancer elimination efforts: Focus on HPV infection, cervical dysplasia, cervical screening and treatment. <i>Preventive Medicine</i> , 2021, 144, 106293.	1.6	10
35	Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care. <i>Scandinavian Journal of Public Health</i> , 2021, 49, 707-712.	1.2	10
36	Elimination of HPV-associated oropharyngeal cancers in Nordic countries. <i>Preventive Medicine</i> , 2021, 144, 106445.	1.6	9

#	ARTICLE	IF	CITATIONS
37	Organized primary human papillomavirus-based cervical screening: A randomized healthcare policy trial. <i>PLoS Medicine</i> , 2021, 18, e1003748.	3.9	9
38	Prospects for accelerated elimination of cervical cancer. <i>Preventive Medicine</i> , 2021, 153, 106827.	1.6	9
39	Baseline findings and safety of infrequent vs frequent screening of human papillomavirus vaccinated women. <i>International Journal of Cancer</i> , 2020, 147, 440-447.	2.3	8
40	High Amounts of SARS-CoV-2 Precede Sickness Among Asymptomatic Health Care Workers. <i>Journal of Infectious Diseases</i> , 2021, 224, 14-20.	1.9	8
41	Antibodies to SARS-CoV-2 and risk of past or future sick leave. <i>Scientific Reports</i> , 2021, 11, 5160.	1.6	8
42	Cost-Effectiveness of Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study. <i>Value in Health</i> , 2021, 24, 1763-1772.	0.1	7
43	Expanding the upper age limit for cervical cancer screening: a protocol for a nationwide non-randomised intervention study. <i>BMJ Open</i> , 2020, 10, e039636.	0.8	7
44	Minor Cytological Abnormalities and up to 7-Year Risk for Subsequent High-Grade Lesions by HPV Type. <i>PLoS ONE</i> , 2015, 10, e0127444.	1.1	7
45	Determinants of the presence of human papillomaviruses in the anal canal of Russian men. <i>Journal of Medical Virology</i> , 2018, 90, 1643-1650.	2.5	6
46	Contraceptive use at first intercourse is associated with subsequent sexual behaviors. <i>Contraception</i> , 2019, 99, 217-221.	0.8	6
47	Emergency contraceptive pill use among women in Denmark, Norway and Sweden: Population-based survey. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 1214-1221.	1.3	6
48	Performance indicators in breast cancer screening in the European Union: A comparison across countries of screen positivity and detection rates. <i>International Journal of Cancer</i> , 2020, 147, 1855-1863.	2.3	6
49	Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening. <i>International Journal of Cancer</i> , 2020, 147, 9-13.	2.3	6
50	Adherence to international recommendations in the governance and organisation of Nordic cervical cancer screening programmes. <i>Acta Oncologica</i> , 2020, 59, 1308-1315.	0.8	5
51	Estimating Total Excess Mortality During a Coronavirus Disease 2019 Outbreak in Stockholm, Sweden. <i>Clinical Infectious Diseases</i> , 2021, 72, e890-e892.	2.9	5
52	Risk for SARS-CoV-2 infection in healthcare workers outside hospitals: A real-life immuno-virological study during the first wave of the COVID-19 epidemic. <i>PLoS ONE</i> , 2021, 16, e0257854.	1.1	5
53	Importance of International Networking and Comparative Research in Screening to Meet the Global Challenge of Cancer Control. <i>JCO Global Oncology</i> , 2020, 6, 180-181.	0.8	4
54	SARS-CoV-2 infections amongst personnel providing home care services for older persons in Stockholm, Sweden. <i>Journal of Internal Medicine</i> , 2021, 290, 430-436.	2.7	4

#	ARTICLE	IF	CITATIONS
55	Effect of naturally acquired type-specific serum antibodies against human papillomavirus type 16 infection. <i>Journal of Clinical Virology</i> , 2017, 90, 64-69.	1.6	3
56	Exposure Definition in Case-Control Studies of Cervical Cancer Screening: A Systematic Literature Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2154-2166.	1.1	3
57	Potential SARS-CoV-2 infectiousness among asymptomatic healthcare workers. <i>PLoS ONE</i> , 2021, 16, e0260453.	1.1	3
58	Commentary: Back to the future in cervical screening: applying a contemporary lens to an old controversy. <i>Journal of Clinical Epidemiology</i> , 2020, 127, 218-219.	2.4	2
59	Feasibility of sending a direct send HPV self-sampling kit to long-term non-attenders in an organized cervical screening program. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2022, 268, 68-73.	0.5	2
60	A pilot study of risk-stratified cervical cancer screening. <i>Open Research Europe</i> , 0, 1, 84.	2.0	0
61	Colposcopic performance in a birth cohort previously eligible for human papillomavirus vaccination. <i>American Journal of Obstetrics and Gynecology</i> , 2021, , .	0.7	0